M&A / Acquisition · Southeast Asia · Announced 3 Apr 2026
Lotus Pharmaceutical → Sandoz Philippines
Taiwan's Lotus Pharmaceutical is buying Sandoz's Philippines business — a generics and biosimilars book weighted to cardiovascular and oncology — adding a Southeast Asian commercial platform as Sandoz hands a market to a regional operator.
Parties: Lotus Pharmaceutical (Taiwan) → Sandoz Philippines (Sandoz AG's Philippines business) (Philippines)
- Deal type
- M&A / Acquisition
- Value
- Undisclosed
- Territory
- Philippines
- Therapeutic area
- Multi-therapy
- Asset
- Sandoz's Philippines business — generics and biosimilars (~40% cardiovascular, ~25% oncology, ~10% anti-infectives); ~80 employees
- Announced
- 3 Apr 2026
Our analysis
Why this matters
Lotus Pharmaceutical of Taiwan has agreed to acquire Sandoz's business in the Philippines. Lotus will take over sales and marketing of the existing portfolio — mainly generics and biosimilars — and about 80 Sandoz Philippines employees are expected to join it. Closing was expected in the second quarter of 2026.
Two strategies meet here. Global generics companies are concentrating on markets where they have scale and handing smaller affiliates to regional operators; Asian mid-caps are buying those affiliates to build multi-country platforms with established brands and teams. The Philippines, with a large out-of-pocket retail market and a growing hospital segment, is a natural place for that transfer.
The full analysis is free to read with a work email on this page.
Source: BioSpectrum Asia